Prestige Consumer Healthcare Inc. (NYSE:PBH) Short Interest Update

Prestige Consumer Healthcare Inc. (NYSE:PBH) was the recipient of a large decline in short interest in the month of February. As of February 15th, there was short interest totalling 1,680,000 shares, a decline of 18.8% from the January 31st total of 2,070,000 shares. Currently, 3.4% of the company’s shares are short sold. Based on an average daily volume of 286,900 shares, the short-interest ratio is presently 5.9 days.

Hedge Funds Weigh In On Prestige Consumer Healthcare

A number of hedge funds and other institutional investors have recently modified their holdings of PBH. Creative Planning boosted its position in Prestige Consumer Healthcare by 32.6% during the 3rd quarter. Creative Planning now owns 10,011 shares of the company’s stock valued at $722,000 after acquiring an additional 2,460 shares in the last quarter. Private Advisor Group LLC lifted its stake in shares of Prestige Consumer Healthcare by 15.6% during the 3rd quarter. Private Advisor Group LLC now owns 3,380 shares of the company’s stock worth $244,000 after purchasing an additional 457 shares during the last quarter. International Assets Investment Management LLC boosted its position in Prestige Consumer Healthcare by 7,112.5% during the third quarter. International Assets Investment Management LLC now owns 1,154 shares of the company’s stock valued at $83,000 after purchasing an additional 1,138 shares in the last quarter. First Trust Direct Indexing L.P. grew its stake in Prestige Consumer Healthcare by 5.7% in the third quarter. First Trust Direct Indexing L.P. now owns 5,016 shares of the company’s stock valued at $362,000 after purchasing an additional 272 shares during the last quarter. Finally, US Bancorp DE raised its holdings in Prestige Consumer Healthcare by 20.3% in the third quarter. US Bancorp DE now owns 3,978 shares of the company’s stock worth $287,000 after purchasing an additional 672 shares in the last quarter. 99.95% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. DA Davidson increased their price objective on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a research report on Friday, February 7th. Oppenheimer raised their price target on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an “outperform” rating in a research note on Thursday, February 13th. Sidoti downgraded Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective on the stock. in a research report on Monday, December 9th. Canaccord Genuity Group increased their target price on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, February 7th. Finally, StockNews.com raised shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Friday, January 24th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, Prestige Consumer Healthcare has an average rating of “Moderate Buy” and a consensus target price of $92.60.

Prestige Consumer Healthcare Stock Down 0.1 %

NYSE PBH traded down $0.05 on Tuesday, reaching $85.20. 136,057 shares of the stock traded hands, compared to its average volume of 312,787. Prestige Consumer Healthcare has a 12 month low of $62.35 and a 12 month high of $88.36. The company has a market cap of $4.22 billion, a price-to-earnings ratio of 19.95, a PEG ratio of 2.69 and a beta of 0.50. The company has a fifty day moving average price of $80.18 and a 200-day moving average price of $77.40. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.20 and a current ratio of 3.68.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. As a group, research analysts forecast that Prestige Consumer Healthcare will post 4.5 EPS for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.